Puma Biotechnology (PBYI) Times Interest Earned (2012 - 2026)
Puma Biotechnology's (PBYI) quarterly Times Interest Earned came in at -$0.91 in Q1 2026, down 322.28% YoY from $0.41 in Q1 2025, and down 108.7% on a QoQ basis from $10.49 in Q4 2025.
Puma Biotechnology (PBYI) Times Interest Earned (2012 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 15 years of Times Interest Earned data on file, last reported at -$0.91 in Q1 2026.
- Quarterly Times Interest Earned fell 322.28% year-over-year to -$0.91 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.03 (up 83.13% YoY) and the FY2025 annual result came in at $3.85, up 4165.25% from the prior year.
- Times Interest Earned declined to -$0.91 in Q1 2026, from $10.49 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $12.6 in Q3 2024 to a low of -$0.91 in Q1 2026.
- A 5-year average of $2.33 and a median of $0.68 in 2025 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2024 — Times Interest Earned jumped 1323.89% — and 2026, when it sank 322.28%.
- Tracing PBYI's Times Interest Earned over 5 years: stood at $4.99 in 2022, then sank by 71.02% to $1.45 in 2023, then surged by 304.09% to $5.85 in 2024, then surged by 79.39% to $10.49 in 2025, then tumbled by 108.7% to -$0.91 in 2026.
- The last three Times Interest Earned figures came in at -$0.91 (Q1 2026), $10.49 (Q4 2025), and $0.99 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 1.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.01 |
| Mar 31, 2026 | -0.91 |
| Dec 31, 2025 | 10.49 |
| Sep 30, 2025 | 0.99 |
| Jun 30, 2025 | 0.68 |
| Mar 31, 2025 | 0.41 |
| Dec 31, 2024 | 5.85 |
| Sep 30, 2024 | 12.60 |
| Jun 30, 2024 | -0.21 |
| Mar 31, 2024 | -0.24 |
| Dec 31, 2023 | 1.45 |
| Sep 30, 2023 | 0.89 |
| Jun 30, 2023 | 0.50 |
| Mar 31, 2023 | 0.45 |
| Dec 31, 2022 | 4.99 |
| Sep 30, 2022 | 0.30 |
| Jun 30, 2022 | 1.51 |
| Mar 31, 2022 | -0.09 |
| Dec 31, 2021 | 0.59 |
| Sep 30, 2021 | 1.58 |